Clinical trial
Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast…
NCT00006825 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00006825 |
|---|---|
| Title | Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer |
| Official title | A Safety Study Of Doxil And Herceptin In Patients With Advanced Her-2 Overexpressing Breast Cancer |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, pegylated liposomal doxorubicin hydrochloride |
| Start date | Jul 1, 2000 |
| Primary completion | Jul 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 28, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: